John Mack

John Mack serves as COO /President Diabetomics, Inc. at DiabetOmics. DiabetOmics operates in the medical devices sector with approximately 24.0 employees. The company is headquartered in Portland, Oregon. DiabetOmics generates annual revenue of 3000000.0. To date, DiabetOmics has raised 14800000.0 in total funding, with the most recent round being Other.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 825 executive contacts are available in Oregon.
• • Our database includes 201,467 c suite-level executives.

Gmail Blue Host Google Apps Remote

medical equipment manufacturing point-of-care testing preeclampsia gestational diabetes diabetes monitoring non-invasive tests saliva test early detection tests autoimmune diabetes risk assessment diagnostic biomarkers glycosylated fibronectin rapid tests maternal health home testing blood glucose salivary diagnostics type-1 diabetes lada patient-centric diagnostics real-time data diagnostic accuracy clinical decision support fda approved iso certified clinical trials maternal health innovation healthcare technology patient monitoring blood sample alternatives autoantibody testing quantitative testing maternal-fetal health blood pressure monitoring disease prediction monitoring therapies health outcome improvement public health economic burden alleviation clinical workflow enhancement medical diagnostics low-resource settings patient education healthcare accessibility rapid results symptom recognition ecological validity pregnancy safety healthcare solutions patient engagement biomedical research medical devices hospital & health care health care health wellness & fitness

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like John Mack in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at DiabetOmics.

John Mack's Position in the MessageCEO Database

• •John Mack is 1 of 1 verified executive contact we track at DiabetOmics.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •766 verified executive contacts in Oregon are in the database.
• •38 verified contacts work at medical devices companies in the 24.0 employee range (same size as DiabetOmics).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated August 2026.

How do I reach John Mack directly?

John Mack's verified email address is available to MessageCEO Pro subscribers. They currently serve as COO /President Diabetomics, Inc. at DiabetOmics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does John Mack work for?

John Mack is COO /President Diabetomics, Inc. at DiabetOmics, a company in the medical devices sector with 24.0 employees. The company is based in Portland, Oregon.

Can I pitch or sell to John Mack?

As COO /President Diabetomics, Inc. at DiabetOmics, John Mack is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach John Mack directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is John Mack in?

John Mack works in the medical devices industry as COO /President Diabetomics, Inc. at DiabetOmics. MessageCEO provides verified contact information for executives across all major industries.

Is John Mack's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. John Mack's profile is kept up-to-date with the latest available information.

Last updated: August 18, 2026